FLT3-IN-32 is a potent FLT3 inhibitor with high selectivity, effectively suppressing FLT3 activating mutations and inducing apoptosis. It demonstrates good tolerance in non-tumor-bearing mice. In NOD/SCID mice loaded with MV4-11 cells, FLT3-IN-32 exhibits outstanding antitumor efficacy, significantly extending mouse survival. FLT3-IN-32 is applicable for acute myeloid leukemia research.

FLT3-IN-32 (Compound 29c) effectively suppresses the proliferation of Ba/F3 cells expressing four mutant FLT3 subtypes, within a concentration range of 0.3-218.7 nM over 72 hours. This compound demonstrates good selectivity and safety towards FLT3-ITD positive cells at concentrations between 1 μM and 1 M. In addition, FLT3-IN-32 (100-500 nM, 48 h) can induce apoptosis in Ba/F3 cells with mutant FLT3 subtypes. Furthermore, it reduces the phosphorylation levels of FLT3 and its downstream signaling molecules, STAT5 and MAPK, at concentrations of 1-50 nM over 4 hours.

FLT3-IN-32 (Compound 29c) administered orally at doses of 20-75 mg/kg once daily for 5 days demonstrates significant antitumor activity in NOD/SCID mice bearing MV4-11 cells.